A Phase 2 interventional study of Physical therapy group and Astragalus in Parkinsonism, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Fujian Medical University Union Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Parkinsonian Disorders with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Parkinsonian Disorders · China.
Among the 21 studies in Parkinsonian Disorders with a site in China, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 2, reaches primary completion later than 0 of the 16 other live ones, and was the 5th registered.
218 studies on the registry are indexed under Parkinsonian Disorders; 63 are open to participants now.
Browse Parkinsonian Disorders studies →17 of the 21 studies in Parkinsonian Disorders with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University · Sites in China
Ages 18–90 · Healthy volunteers
Tianjin Huanhu Hospital · Sites in China
Ages 30–85
Peking University First Hospital · Sites in China
Ages 30–80
Wang Ping · Sites in China
Ages 18–100
Xuanwu Hospital, Beijing · Sites in China
Ages 19–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Parkinsonian Disorders studies recruiting now, 18 (40%) set no upper age limit and 9 (20%) stop at 75 or younger; 4 take children under 18; 12 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 40 is below the median of 50 across 137 interventional studies indexed under Parkinsonian Disorders.
Median enrollment 59 across the 14 interventional studies, 640 across the 7 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.
Fujian Medical University Union Hospital has 1 study filed under Parkinsonian Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Parkinsonian Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05171205Ruijin HospitalSpinal Cord Stimulation for Parkinsonism | 2026-12-31 |
| NCT07176091Second Affiliated Hospital of Soochow UniversityClinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's Disease | 2027-03-01 |
| NCT07570212Peking University First HospitalIndividualized Transcranial Magnetic Stimulation in Parkinsonian Disorders | 2027-09-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Parkinsonian Disorders with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. However, there is still a lack of research on the treatment for non-motor symptoms of α-synucleinopathy, especially autonomic dysfunctions such as orthostatic hypotension. Efficacy and safety of astragalus for non-motor symptoms of α-synucleinopathy will be assessed by an open-label self-controlled before-and-after study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Astragalus
Behavioral: Physical therapy group
Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
Change from baseline mean arterial pressure after 3 minutes of upright posture versus decubitus position (mmHg) at 3 months.
Mean arterial pressure was calculated as ⅓ pulse pressure + diastolic pressure.
Time frame: Baseline vs 3 months after treatment.
OH Questionnaire score
ΔHR/ΔSBP means heart rate (HR) and systolic blood pressure (SBP) from baseline OH Questionnaire score
Time frame: Baseline vs 3 months after treatment.
Change from baseline Rate of change in ΔHR/ΔSBP at 3months.
ΔHR/ΔSBP means heart rate (HR) and systolic blood pressure (SBP) from baseline lying position to standing for 3 minutes
Time frame: Baseline vs 3 months after treatment.
Change from baseline HRV (ms) at 3months.
Heart rate variability (HRV) was calculated as the maximum bpm - minimum bpm.
Time frame: Baseline vs 3 months after treatment.
Change from baseline decumbent and orthostatic digit span (DDS) difference at 3months.
DDS is an executive function measurement tool
Time frame: Baseline vs 3 months after treatment.
Change from baseline decumbent and orthostatic character conversion (CDS) difference at 3months.
CDS is an executive function measurement tool
Time frame: Baseline vs 3 months after treatment.
Change from baseline MoCA scores at 3 months.
The Montreal Cognitive Assessment (MoCA)
Time frame: Baseline vs 3 months after treatment.
Change from baseline CDR scores at 3 months.
The Clinical Dementia Rating (CDR)
Time frame: Baseline vs 3 months after treatment.
Change from baseline RAVLT scores at 3 months.
The Rey Auditory Verbal Learning Test (RAVLT)
Time frame: Baseline vs 3 months after treatment.
Change from baseline HAS scores at 3 months.
The Hamilton Anxiety Scale (HAS)
Time frame: Baseline vs 3 months after treatment.
Change from baseline HDS scores at 3 months.
The Hamilton Depression Scale (HDS)
Time frame: Baseline vs 3 months after treatment.
Change from baseline NPI scores at 3 months.
The Neuropsychiatric Inventory (NPI)
Time frame: Baseline vs 3 months after treatment.
Change from the baseline plasma α-synuclein levels (ng/ml) at 3 months.
Time frame: Baseline vs 3 months after treatment.
Change from baseline Vic at 3 months.
The intra-cellular compartment (Vic) of the Neurite Orientation Dispersion and Density Imaging (NODDI) model represents diffusion within the axons and cells.
Time frame: Baseline vs 3 months after treatment.
Change from baseline ODI at 3 months.
NODDI models the dispersion of axonal fibers with the use of an Orientation Dispersion Index (ODI).
Time frame: Baseline vs 3 months after treatment.
Change from baseline PAF (Hz) at 3 months.
The alpha-peak frequency (PAF) is the frequency with the highest power within the alpha-band.
Time frame: Baseline vs 3 months after treatment.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2023; primary completion for Jul 2024, 9 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fujian Medical University Union Hospital →